129 related articles for article (PubMed ID: 2713488)
21. Response to intermediate and standard doses of IFN-beta in hairy-cell leukaemia.
Liberati AM; Fizzotti M; Di Clemente F; Senatore M; Berruto P; Falini B; Martelli MF; Grignani F
Leuk Res; 1990; 14(9):779-84. PubMed ID: 2232850
[TBL] [Abstract][Full Text] [Related]
22. Minimal interferon-alpha doses for hairy cell leukemia.
Gastl G; Aulitzky W; Tilg H; Thaler J; Berger M; Huber C
Blood; 1990 Feb; 75(3):812-3. PubMed ID: 2297581
[No Abstract] [Full Text] [Related]
23. The alpha 2 (r) interferon in the treatment of hairy cell leukemia: progressive report of 25 cases.
Mandelli F; Cafolla A; Annino L; Amadori S; Gentile A; Bianco P; Dianzani F
J Biol Regul Homeost Agents; 1987; 1(4):177-82. PubMed ID: 3332545
[TBL] [Abstract][Full Text] [Related]
24. Recombinant alpha-interferon (alpha-IFN) for progressive hairy-cell leukemia (HCL): a study in previously untreated nonsplenectomized patients.
Schwarzinger I; Bettelheim P; Chott A; Herold C; Hinterberger W; Köller U; Kos M; Neumann E; Radaszkiewicz T; Lechner K
Wien Klin Wochenschr; 1988 Jan; 100(2):47-51. PubMed ID: 3348041
[TBL] [Abstract][Full Text] [Related]
25. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up.
Boussiotis VA; Pangalis GA
Br J Haematol; 1991 Oct; 79 Suppl 1():30-3. PubMed ID: 1931705
[TBL] [Abstract][Full Text] [Related]
26. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine.
Seymour JF; Estey EH; Keating MJ; Kurzrock R
Leukemia; 1995 May; 9(5):929-32. PubMed ID: 7769859
[TBL] [Abstract][Full Text] [Related]
27. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
Bergsagel DE; Messner H
Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
[TBL] [Abstract][Full Text] [Related]
28. [Effectiveness of gamma interferon and alpha interferon in hairy cell leukemia].
Niederle N; Doberauer C; Kloke O; Höffken K; Schmidt CG
Klin Wochenschr; 1987 Jul; 65(14):706-12. PubMed ID: 3114551
[TBL] [Abstract][Full Text] [Related]
29. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a.
Berman E; Heller G; Kempin S; Gee T; Tran LL; Clarkson B
Blood; 1990 Feb; 75(4):839-45. PubMed ID: 2302457
[TBL] [Abstract][Full Text] [Related]
30. Cost-benefit analysis of interferon alfa-2b in treatment of hairy cell leukemia.
Ozer H; Golomb HM; Zimmerman H; Spiegel RJ
J Natl Cancer Inst; 1989 Apr; 81(8):594-602. PubMed ID: 2495367
[TBL] [Abstract][Full Text] [Related]
31. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
32. Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses.
Cetto GL; Franceschi T; Turrina G; Chiarion-Sileni V; Capelli MC; Bellini A; Paccagnella A; Bassetto MA; Molino AM; de Sandre G
Semin Surg Oncol; 1988; 4(3):184-90. PubMed ID: 3055162
[TBL] [Abstract][Full Text] [Related]
33. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.
Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inverardi D; Bernasconi P; Mancini M; Donti E; Grignani F
Blood; 1988 Aug; 72(2):642-7. PubMed ID: 3165298
[TBL] [Abstract][Full Text] [Related]
34. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
Spiegel RJ; Jacobs SL; Treuhaft MW
J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
[TBL] [Abstract][Full Text] [Related]
37. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
[TBL] [Abstract][Full Text] [Related]
38. [Primary treatment of hairy cell leukemia with low-dose human recombinant interferon-alpha-2c (Hr-IFn alpha 2c) in comparison with therapy following splenectomy. Interferon (IFn-alpha 2c) in HCL before or after splenectomy].
Pralle H; Zwingers T; Boedewadt S; Bross K; Dörken B; Gamm H; Ho AD; Parwaresch RM; Schmitz N; Papendick U
Onkologie; 1987 Feb; 10(1):5-10. PubMed ID: 3295625
[TBL] [Abstract][Full Text] [Related]
39. Hairy-cell leukemia and alpha-interferon treatment: long-term responders.
Zinzani PL; Lauria F; Salvucci M; Rondelli D; Raspadori D; Bendandi M; Magagnoli M; Tura S
Haematologica; 1997; 82(2):152-5. PubMed ID: 9175317
[TBL] [Abstract][Full Text] [Related]
40. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Ho AD; Thaler J; Mandelli F; Lauria F; Zittoun R; Willemze R; McVie G; Marmont AM; Prümmer O; Stryckmans P
J Clin Oncol; 1989 Oct; 7(10):1533-8. PubMed ID: 2789273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]